Jade Biosciences Inc. reported cash, cash equivalents, and investments of $198.9 million as of September 30, 2025. Following the completion of a $135.0 million private placement in October, the company's cash position increased to approximately $325.6 million on a pro-forma basis as of September 30, 2025. Jade stated that its current cash is expected to fund operating expenses and capital expenditure requirements into the first half of 2028. During the period, Jade presented preclinical safety and biomarker data for JADE101, initiated a Phase 1 healthy volunteer study of JADE101, and introduced JADE201, with a first-in-human trial in rheumatoid arthritis planned for the first half of 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jade Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9575493-en) on November 13, 2025, and is solely responsible for the information contained therein.